Show simple item record

dc.contributor.authorEl-Deeb, Ibrahim Mustafaen_US
dc.contributor.authorYoo, Kyungen_US
dc.contributor.authorLee, Soen_US
dc.date.accessioned2017-04-24T13:35:44Z
dc.date.available2017-04-24T13:35:44Z
dc.date.issued2011en_US
dc.date.modified2014-08-28T22:58:32Z
dc.identifier.issn01986325en_US
dc.identifier.doi10.1002/med.20206en_US
dc.identifier.urihttp://hdl.handle.net/10072/37836
dc.description.abstractROS kinase is one of the last two remaining orphan receptor tyrosine kinases with an as yet unidentified ligand. The normal functions of human ROS kinase in different body tissues have not been fully identified so far. However, the ectopic expression, as well as the production of variable mutant forms of ROS kinase has been reported in a number of cancers, such as glioblastoma multiforme, and non-small cell lung cancer, suggesting a role for ROS kinase in deriving such tumors. It is thought also that c-ROS gene may have a role in some cardiovascular diseases, and the fact that homozygous male mice targeted against c-ROS gene are healthy but infertile, has inspired researchers to think about ROS inhibition as a method for development of new male contraceptives. The recent discovery of new selective and potent inhibitors for ROS kinase, along with the development of new specific diagnostic methods for the detection of ROS fusion proteins, raises the importance of using these selective inhibitors for targeting ROS mutations as a new method for treatment of cancers harboring such genes. This review focuses on the ectopic expression of ROS and its fusion proteins in different cancer types and highlights the importance of targeting these proteins for treatment of substantial cancers. It describes also the recent advances in the field of ROS kinase inhibition, and the potential clinical applications of ROS kinase inhibitors.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.format.extent237410 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherWiley Interscienceen_US
dc.publisher.placeUnited Statesen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom794en_US
dc.relation.ispartofpageto818en_US
dc.relation.ispartofissue5en_US
dc.relation.ispartofjournalMedicinal Research Reviewsen_US
dc.relation.ispartofvolume31en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchPharmaceutical Sciencesen_US
dc.subject.fieldofresearchcode111504en_US
dc.titleROS Receptor Tyrosine Kinase: A New Potential Target for Anticancer Drugsen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyrightCopyright 2010 Wiley Periodicals, Inc. This is the pre-peer reviewed version of the following article: ROS Receptor Tyrosine Kinase: A New Potential Target for Anticancer Drugs, Medicinal Research Reviews, which has been published in final form at http://dx.doi.org/10.1002/med.20206.en_US
gro.date.issued2011
gro.hasfulltextFull Text


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record